Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk
The industry doyen pointed out that 70 percent of the major drugs are in-licensed and it is what India should look to do.
Cipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen Inc.
Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors' clinics or co-packaging on select Cipla brands.
HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 605 in its research report dated February 07, 2019.
ICICI Direct recommended hold rating on Cipla with a target price of Rs 545 in its research report dated February 07, 2019.
"We spent a lot of time just making sure that we started with $100 million trajectory and how do we take it closer to $125 that we want to exit at," Vohra said.
The city-based firm in a statement said it has received final approval for its ANDA for Tadalafil tablets 20 mg from the United States Food and Drug Administration (USFDA).
EBITDA margin is likely to contract by 325 bps YoY to 17.7% due to high material cost and muted sales growth in domestic business, Reliance Securities said
Net Sales are expected to increase by 6.9 percent Y-o-Y (up 4.3 percent Q-o-Q) to Rs. 4,185.8 crore, according to Sharekhan.
Net Sales are expected to increase by 4.3 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 4,081.6 crore, according to ICICI Direct.
HSBC said risk-reward turned favourable post corrections in Cadila Healthcare & Cipla.
This is the verbatim transcript of Cipla management call with analysts.
Cipla sells a range of products including pills, nasal sprays and inhalers to treat respiratory diseases.
HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 605 in its research report dated December 26, 2018.
The market is expected to cool off a bit in the near-term after the recent rally. It is advisable to stick to large-caps and quality mid-cap names
In coming week any tick above 9,350 on Nifty Pharma index will trigger fresh buying in pharma stocks, Arpan Shah of Monarch Networth Capital said
The S&P BSE Sensex lost over 1200 points while for the Nifty the cut was a little over 400 points or 3.7 percent since September 28.
ICICI Direct recommended hold rating on Cipla with a target price of Rs 510 in its research report dated November 06, 2018.
"At the first stage closing, InvaGen or its affiliates will acquire, through the issuance by Avenue of new shares, shares representing a 33.3 per cent stake in Avenue's capital stock on a fully diluted basis for USD 35 million," Cipla said in a regulatory filling.
The Q2FY19 earnings season so far has been in line with the expectations. Strong results declared by IT companies, upbeat numbers from RIL and robust growth reported by the FMCG companies are indicative of sustained demand environment.
Valganciclovir tablets are used in the treatment cytomegalovirus infection (serious viral eye infection of the retina) in AIDS patients and in prevention of cytomegalovirus (CMV) disease after organ transplant.
Trends on SGX Nifty indicate a negative opening for the broader index in India, a fall of 31 points or 0.29 percent. Nifty futures were trading around 10,591-level on the Singaporean Exchange.